Camurus AB (CAMX)
Nasdaq Stockholm · Sweden · prices in SEK · close of 27 Oct 2026
Key indicators
| Last close | SEK 663.00 |
|---|---|
| 52-week range | 430.80 – 710.00 |
| Return, 1 month / 3 months | +7.6% / +7.5% |
| Return, 1 year / 3 years | +6.2% / +104.0% |
| Trend | Uptrend |
| RSI (14) | 63 |
| Volatility (1 year) | 49.1% |
| Worst drawdown (1 year) | -37.9% |
| Average daily value traded | 51.07M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Camurus AB is a pharmaceutical company based in Lund, Sweden, that develops and commercialises medicines formulated with its own lipid-based drug delivery technology. Its products are long-acting injectable and oral formulations designed to release medicine gradually in the body. The company's portfolio includes treatments for opioid dependence and for painful conditions of the mouth, and it works with partners to make these products available in markets around the world. Its customers are healthcare providers and patients through prescription medicines.
The shares are listed on the Nasdaq Stockholm in Sweden under the code CAMX, and the price on this page is in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Camurus AB (CAMX) trades on the Nasdaq Stockholm in Sweden. It last closed at SEK 663.00 on 27 October 2026.
Its price-based Market X-Ray is 74 out of 100 (a strong price profile), ranking 136 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 6.2% and over the last three months it rose 7.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Stockholm
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 84 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 15.4% | ||
| From 52-week high | -5.8% | ||
| Momentum | 74 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 7.5% | ||
| 6-month return | 23.3% | ||
| 12-month return, skipping the last month | -1.4% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 49.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.9% | ||
| Liquidity | 92 · Strong | Trades actively. | |
| Average daily value traded | 51.07M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −0.2% |
|---|---|
| 1 month | +7.6% |
| 3 months | +7.5% |
| 6 months | +23.3% |
| 1 year | +6.2% |
| 3 years | +104.0% |
| 5 years | +295.6% |
Signals
| 50-day / 200-day average | 619.93 / 574.37 |
|---|---|
| Golden / death cross (60 days) | Golden, 55 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 17.33 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Stockholm; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.